Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal

BACKGROUND: Safety and efficacy of pembrolizumab, a humanized programmed death 1 monoclonal antibody, was assessed in KEYNOTE-028, a multicohort, phase Ib trial for patients with programmed death ligand 1 (PD-L1)-positive advanced solid tumors. We report results for the cohort of patients with advan...

Descripción completa

Detalles Bibliográficos
Autores principales: Ott, P. A., Piha-Paul, S. A., Munster, P., Pishvaian, M. J., van Brummelen, E. M. J., Cohen, R. B., Gomez-Roca, C., Ejadi, S., Stein, M., Chan, E., Simonelli, M., Morosky, A., Saraf, S., Emancipator, K., Koshiji, M., Bennouna, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406758/
https://www.ncbi.nlm.nih.gov/pubmed/28453692
http://dx.doi.org/10.1093/annonc/mdx029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406758/
https://www.ncbi.nlm.nih.gov/pubmed/28453692
http://dx.doi.org/10.1093/annonc/mdx029

Ejemplares similares